Sahil A. Parikh

Nov 27, 2024 | radcliffecardiology.com | Ashley Park |Marc P. Bonaca |Sahil A. Parikh |Felix Mahfoud

AHA Conference 2024 - New insights from the CLEAR OUTCOMES trial investigating bempedoic acid (Esperion Therapeutics Inc.) in statin-intolerant patients with peripheral arterial disease (PAD). Dr Marc Bonaca (University of Colorado School of Medicine, Colorado, US) joins us onsite at AHA Conference to discuss new insights from CLEAR OUTCOMES (NCT02993406).

Nov 4, 2024 | radcliffecardiology.com | Mirvat Alasnag |Sahil A. Parikh |David Erlinge |Stephan Baldus

Skip to main content Video Published: Views: 18 Likes: 0 Average (ratings) TCT Conference 2024 - Join us for an engaging conversation with TCT Programme Director, Dr Sahil Parikh (Columbia University Irving Medical Center, US), as he delivers a concise and insightful overview of key late-breaking trials from the TCT 24 Conference.

Apr 29, 2024 | healio.com | Richard Smith |Sahil A. Parikh

You've successfully added to your alerts. You will receive an email when new content is published. Click Here to Manage Email Alerts We were unable to process your request. Please try again later. If you continue to have this issue please contact [email protected]. Key takeaways: The FDA approved a novel bioresorbable scaffold for the treatment of chronic limb-threatening ischemia. The approval was based on the results of the LIFE-BTK trial presented at TCT 2023.

Nov 20, 2023 | evtoday.com | Sahil A. Parikh |Peter Schneider

William A. Gray, MD Division of Cardiology Lankenau Heart Institute/Main Line Health Wynnewood, Pennsylvania [email protected] Twitter: @DrBillGray Sahil A. Parikh, MD Columbia University Irving Medical Center New York, New York [email protected] Twitter: @sahilparikhmd Peter A.

Oct 24, 2023 | thelancet.com | Sahil A. Parikh |Peter Schneider |Endovascular Surgery

Numerous randomised clinical trials and real-world studies have supported the safety of paclitaxel-coated devices for the treatment of femoropopliteal occlusive disease. However, a 2018 summary-level meta-analysis suggested an increased mortality risk for paclitaxel-coated devices compared with uncoated control devices. This study presents an updated analysis of deaths using the most complete and current data available from pivotal trials of paclitaxel-coated versus control devices.